Letter to the Editor

The apolipoprotein E ϵ 4 allele is no risk factor for prostate cancer in the Norwegian population

Sir,

In 1998 a letter was published in the *British Journal of Cancer* (Lehrer et al, 1998) reporting increased frequency of the apolipoprotein E ϵ 4 allele among patients with prostate cancer, and thereby suggests this allele as a risk factor for this type of cancer. Lehrer's study was based on examining 35 patients with prostate cancer. A study from Finland ($n = 130$) (Niemi et al, 2000) did not show evidence that any ApoE-phenotype is associated with prostate cancer.

The study of Lehrer (1998) is one of many reports which claims association between ApoE and particular diseases. The ApoE ϵ 4 allele is a strong risk factor for Alzheimer's disease (Strittmatter et al, 1993), and has been reported to be responsible for progression of atherosclerosis (Hixson et al, 1991), amyloidosis in patient with rheumatoid arthritis (Hasegawa et al, 1996), macro- and microangiopathy in diabetic patients (Ukkola et al, 1993) and decreased fertility (Gerdes et al, 1996). Finally, ApoE4 has been reported to have a protective effect against distal colon cancer (Kervinen et al., 1996).

It has been shown that the presence of ApoE has a protective effect on cells in culture due to an anti-oxidative effect, and that the ApoE2 has the largest protective effect, while ApoE4 is the least efficient phenotype for protecting cells from oxidative stress. Since the antioxidant vitamin E has been reported to have a protective effect against prostate cancer (Hartman et al, 1998), it seems reasonable to test the hypothesis that the ϵ 4-allele is a risk factor for prostate cancer.

We have examined the hypothesis by comparing the distribution of apoE genotypes in 230 Norwegian patients (< 70 years) with prostate cancer to the distribution found in a recent study of 798 Norwegian blood donors (Kumar et al, submitted). ApoE-genotyping was carried out by polymerase chain reaction (Hixson and Vernier, 1990). The frequency of the ϵ 4-allele in the patient population was 0.187, while the frequency of the ϵ 4-allele in the control population was 0.198. This implies that there is no significant difference between the prostate cancer population and the normal population with respect to the frequency of the ϵ 4-allele. The ϵ 4/ ϵ 4-homozygosity appeared at a rate of 0.036 in the prostate cancer population, while a rate of 0.040 was observed for the normal Norwegian population (Kumar et al, submitted). This difference is also non-significant.

In conclusion, our data do not support the hypothesis that the ϵ 4-allele is a risk factor for prostate cancer.

N Wessel¹, K Liestøl², J Mæhlen³ and SH Brorson³

¹Department of Urology, Ullevål Hospital, Oslo, Norway; ²Department of Informatics, University of Oslo, Oslo, Norway; and ³Department of Pathology, Ullevål Hospital, Oslo, Norway

REFERENCES

- Gerdes LU, Gerdes Chr, Hansen PS, Klausen Chr and Færgeman O (1996) Are men carrying the apolipoprotein E4 or E2 allele less fertile than ϵ 3 ϵ 3 genotypes. *Hum Genet* **98**: 239–242
- Hartman TJ, Albanes D, Pietinen P, Hartman AM, Rautalahti M, Tangrea JA and Taylor PR (1998) The association between baseline vitamin E, selenium, and prostate cancer in the alpha-tocopherol, beta-carotene cancer prevention study. *Cancer Epidemiol Biomarkers Prev* **7**: 335–340
- Hasegawa H, Nishi S, Ito S, Saeki T, Kuroda T, Kimura H, Watababe T, Nakano M, Gejyo F and Arakawa M (1996) High prevalence of serum apolipoprotein E4 isoprotein in rheumatoid arthritis patients with amyloidosis. *Arthritis Rheum* **39**: 1728–1732
- Hixson JE and PDAY Research group (1991) Apolipoprotein and progression of coronary artery disease evaluated by angiography and clinical events. *Circulation* **88**: 2763–2770
- Hixson JE and Vernier DT (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. *J Lipid Res* **31**: 545–548
- Kervinen K, Södervik H, Makela J, Lehtola J, Niemi M, Kairaluoma MI and Kesaniemi YA (1996) Is the Development of Adenoma and Carcinoma in Proximal Colon Related to Apolipoprotein E Phenotype? *Gastroenterology* **110**: 1785–1790
- Kumar T, Liestøl K, Mæhlen J, Hiort A, Jettstuen E and Brorson SH. Allele frequencies of apolipoprotein E gene polymorphisms in the protein coding region and promotor region (–491 A/T) in a healthy Norwegian population. *Human Biology*. In press, 2001
- Lehrer S (1998) Possible relationship of the apolipoprotein E (ApoE) ϵ 4 allele to prostate cancer. *Br J Cancer* **78**: 1398
- Niemi M, Kervinen K, Kiviniemi H, Lukkarinen O, Kyllonen AP, Apaja-Sarkkinen M, Savolainen MJ, Kairaluoma MI and Kesaniemi YA (2000) Apolipoprotein E phenotype, cholesterol and breast and prostate cancer. *J Epidemiol Community Health* **54**: 938–939
- Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS and Roses AD (1993) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. *Proc Natl Acad Sci USA* **90**: 1977–1981
- Ukkola O, Kervinen K, Salmela PI, von Dickhoff K, Laakso M and Kesaniemi YA (1993) Apolipoprotein E phenotype is related to macro- and microangiopathy in patients with non-insulin-dependent diabetes mellitus. *Atherosclerosis* **101**: 9–15